TiGenix NV Share Price

Stocks

28/03/18	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
01/02/18	Takeda Pharmaceutical : Japan's Takeda hikes outlook on cancer drug sales, third quarter profit jumps	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
08/01/18	Takeda Pharmaceutical : Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid	RE
08/01/18	Takeda Pharmaceutical : $11 billion biotech binge fuels forecasts of 2018 M&A surge	RE
04/10/12	GALAPAGOS : Maturing Belgian biotechs outshine European peers	RE

31/07/18	TiGenix : Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (EN - NL - FR - ES)	PU
31/07/18	TiGenix : Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period	GL
23/07/18	TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007	GL
06/07/18	TiGenix : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Obligations (EN – NL – FR – ES)	PU
06/07/18	TiGenix : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid	GL

31/07/18	TiGenix : Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait
23/07/18	Le Graph du Jour : 29% des biotechs en territoire positif depuis leur IPO sur Euronext
06/07/18	TiGenix : Takeda et TiGenix annoncent les résultats de la deuxième période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix
13/06/18	TiGenix : annonce un changement dans son conseil d'administration et son équipe de direction
06/06/18	TiGenix : Takeda et TiGenix annoncent les résultats de la première période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix et le début de la deuxième période d'accep...

Manager	Title	Age	Since
Wilfried Dalemans CTO	Chief Tech/Sci/R&D Officer	68	-
Koen Huygens PRN	Corporate Officer/Principal	-	30/06/2001
Julian Panes PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Sebastian Wehle BRD	Director/Board Member	-	14/06/2018
Jean Stephenne CHM	Chairman	77	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIGENIX NV	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	64.38B
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	56.16B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	54.16B
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	45.33B
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	42.25B
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	40.78B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	33.8B
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.73%	-3.28%	+21.10%	-12.28%	23.57B
Average	-0.20%	+4.50%	+52.22%	+162.51%	43.63B
Weighted average by Cap.	+0.00%	+3.60%	+49.16%	+161.39%